In conclusion, our studies bring forward two novel targets XPO1 and PAK4 as actionable therapeutic avenues to overcome resistance to lenvatinib in refractory anaplastic thyroid cancer. The gene discussed is XPO1; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.